KeyBanc last night initiated coverage of RadNet (RDNT) with an Overweight rating and $92 price target The firm believes outpatient diagnostic imaging is an attractive subsector, supported by “powerful” growth drivers including hospital-to-outpatient shift and growing demand for advanced imaging. RadNet’s targets for 2025 through 2028 “seem very reasonable,” especially in the context of better Medicare rates, potential for capital deployment upside, and ramping AI benefits, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDNT:
- RadNet initiated with an Overweight at KeyBanc
- RadNet acquires Radiology Regional, terms not disclosed
- RadNet names Mital Patel as COO, announces expanded executive roles
- Oncology Institute appoints Mark Stolper to board of directors
- RadNet’s Strategic Growth and AI Success Justify Buy Rating Despite Concerns